SynCAM3 has also been reported to inhibit glioma tumorigenesis by regulating histone deacetylation, to serve as a potential marker for the diagnosis of Alzheimer’s disease due to the significantly high expression of SynCAM3 in a pyroglutamate modified amyloid β-expressing transgenic mice model, and to be implicated in neuron degeneration caused by neuromuscular junction impairments and the reduction of extracellular matrix (ECM) integrity under conditions of low SynCAM3 expression [22,23,24]. The gene discussed is CADM3; the disease is early-onset autosomal dominant Alzheimer disease.